文献速递消化道肿瘤与早癌

低剂量阿司匹林与结直肠癌预防:挪威全国登记队列研究

Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway.
PubMed 文献 · Am J Gastroenterol · 2024-02-01

该全国性队列纳入2004-2018年挪威50岁以上人群2,186,390人,中位随访10.9年,评估低剂量阿司匹林使用与结直肠癌风险的关系。结果显示当前使用与结直肠癌风险降低相关(HR 0.87),且对转移性结直肠癌关联更强,使用时长与风险降低呈显著趋势。

要点

  • 当前低剂量阿司匹林使用与结直肠癌风险降低13%相关(HR 0.87)。
  • 使用时长与风险降低呈剂量-效应趋势,≥5年者HR 0.84。
  • 对转移性结直肠癌的关联强于局部或区域期癌。

核心结论

  • 低剂量阿司匹林使用与结直肠癌风险降低相关,且使用时间越长风险越低。

研究设计与样本

  • 全国性登记队列研究,纳入2004-2018年挪威50岁及以上居住满6个月者,共2,186,390人。

主要发现

  • 中位随访10.9年,579,196人(26.5%)使用低剂量阿司匹林,38,577人(1.8%)诊断为结直肠癌。
  • 当前使用 vs 从未使用与结直肠癌风险降低相关(HR 0.87,95%CI 0.84-0.90)。
  • 转移性结直肠癌HR 0.79(95%CI 0.74-0.84),区域期HR 0.89(95%CI 0.85-0.92),局部期HR 0.93(95%CI 0.87-1.00),异质性P=0.001。
  • 当前使用时长与风险呈显著趋势:<3年HR 0.91(95%CI 0.86-0.95),≥3且<5年HR 0.85(0.80-0.91),≥5年HR 0.84(0.80-0.88),P趋势<0.001。
  • 过去使用 vs 从未使用:<3年HR 0.89(95%CI 0.84-0.94),≥3且<5年HR 0.90(0.83-0.99),≥5年HR 0.98(0.91-1.06),P趋势<0.001。

关键数值与推荐

  • 研究期间估计低剂量阿司匹林使用避免了1,073例结直肠癌(95%CI 818-1,338)。

临床怎么用

  • 在评估结直肠癌预防策略时,低剂量阿司匹林的长期使用可能与风险降低相关,需结合个体出血风险权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To examine the association between low-dose aspirin use and risk of colorectal cancer (CRC). METHODS: In this nationwide cohort study, we identified individuals aged 50 years or older residing for 6 months or more in Norway in 2004-2018 and obtained data from national registers on drug prescriptions, cancer occurrence, and sociodemographic factors. Multivariable Cox regression models were used to estimate the association between low-dose aspirin use and CRC risk. In addition, we calculated the number of CRC potentially averted by low-dose aspirin use. RESULTS: We included 2,186,390 individuals. During the median follow-up of 10.9 years, 579,196 (26.5%) used low-dose aspirin, and 38,577 (1.8%) were diagnosed with CRC. Current use of aspirin vs never use was associated with lower CRC risk (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.84-0.90). The association was more pronounced for metastatic CRC (HR 0.79; 95% CI 0.74-0.84) than regionally advanced (HR 0.89; 95% CI 0.85-0.92) and localized CRC (HR 0.93; 95% CI 0.87-1.00; P heterogeneity = 0.001). A significant trend was found between duration of current use and CRC risk: HR 0.91 (95% CI 0.86-0.95) for <3 years, HR 0.85 (0.80-0.91) for ≥3 and <5 years, and HR 0.84 (0.80-0.88) for ≥5 years of use vs never use ( P trend < 0.001). For past use, HR were 0.89 (95% CI 0.84-0.94) for <3 years, 0.90 (0.83-0.99) for ≥3 and <5 years, and 0.98 (0.91-1.06) for ≥5 years since last use vs never use ( P -trend < 0.001). We estimated that aspirin use averted 1,073 cases of CRC (95% CI 818-1,338) in the study period. DISCUSSION: In this nationwide cohort, use of low-dose aspirin was associated with a lower risk of CRC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Nafisi S, Støer NC, Veierød MB, et al. Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway. Am J Gastroenterol. 2024. PMID: 38300127. doi:10.14309/ajg.0000000000002695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。